Results 61 to 70 of about 119,519 (336)

JAK1 (Janus kinase 1) [PDF]

Atlas of Genetics and Cytogenetics in Oncology and Haematology, 2011
Review on JAK1 (Janus kinase 1), with data on DNA, on the protein encoded, and where the gene is implicated.
Knoops, L, Hornakova, T, Renauld, JC
openaire   +2 more sources

Down‐regulation of Shh in the hair follicles of mice during chemotherapy‐induced hair loss is mediated by the JAK/STAT1 signaling pathway

FEBS Open Bio, EarlyView.
We found that during chemotherapy‐induced alopecia (CIA), Sonic hedgehog (Shh) expression significantly decreased in hair follicle Shh+ cells, whereas the Janus‐activated kinase/signal transducer and activator of transcription 1 (JAK/STAT1) signaling pathway was markedly activated.
Ruifang Fan, Jingling Huang, Xiang Lin, Tingjiao Lan, Yuli Tang, Ling Sun, Guixuan Zhou   +6 more
wiley   +1 more source

Transgenic Zebrafish as a Novel Animal Model to Study Tauopathies and Other Neurodegenerative Disorders in vivo [PDF]

, 2010
Our ageing society is confronted with a dramatic increase in patients suffering from tauopathies such as Alzheimer's disease, frontotemporal dementia and others.
Haass, Christian, Paquet, Dominik, Schmid, Bettina   +2 more
core   +1 more source

Computational modeling and in vitro evaluation identified natural product—Z218 as a novel Janus kinase 2 (JAK2) inhibitor to combat β‐thalassemia [PDF]

, 2023
Ahmad Shaikh
openalex   +1 more source

Temporal Trends in and Associations With Nonsteroidal Anti‐inflammatory Drug Prescription in Adult and Pediatric Patients With Inflammatory Bowel Disease

Arthritis Care &Research, EarlyView.
Objective Recent inflammatory bowel disease (IBD) treatment guidelines have recommended against nonsteroidal anti‐inflammatory drug (NSAID) use despite prevalent musculoskeletal symptoms and opioid overuse in this population. Given the discordance between changing national guidelines and potential clinical utility, we sought to assess national temporal
Adam S. Mayer, Rui Xiao, Andrew Grossman, Meenakshi Bewtra, Michael D. George, Pamela F. Weiss   +5 more
wiley   +1 more source

Tofacitinib successful treatment of idiopathic twenty-nail dystrophy: a case report

Journal of Dermatological Treatment
Purpose Twenty-nail dystrophy (TND) is a chronic nail disorder affecting all or some nails and posing a significant therapeutic challenge for dermatologists.
Wenjun Zhao, Shijun Shan, Dongmei Liu
doaj   +1 more source

Janus kinase inhibitors in autoimmune bullous diseases

Frontiers in Immunology, 2023
Autoimmune bullous disease (AIBD) is a severe skin disorder caused by autoantibodies that target intercellular or cell-matrix adhesion proteins.
Dawei Huang, Dawei Huang, Yuexin Zhang, Yuexin Zhang, Luyang Kong, Luyang Kong, Jiajing Lu, Jiajing Lu, Yuling Shi, Yuling Shi   +9 more
doaj   +1 more source

Signal transducer and activator of transcription 2 deficiency is a novel disorder of mitochondrial fission [PDF]

, 2015
Defects of mitochondrial dynamics are emerging causes of neurological disease. In two children presenting with severe neurological deterioration following viral infection we identified a novel homozygous STAT2 mutation, c.1836C4A (p.Cys612Ter), using ...
Anderson, G, Cale, CM, Chalasani, A, Chan, E, Duchen, MR, Gilmour, KC, Hambleton, S, Jacques, S, Osellame, LD, Plagnol, V, Qasim, W, Rahman, S, Shahni, R, Taanman, JW, Wadatilake, Y   +14 more
core   +1 more source

Sarilumab in Polyarticular‐Course Juvenile Idiopathic Arthritis: Dose‐Finding and One‐Year Analysis of a Phase 2b, Open‐Label, Multicenter Study

Arthritis Care &Research, Accepted Article.
Objective This study assessed sarilumab in treating patients with polyarticular‐course juvenile idiopathic arthritis (pcJIA). Methods This phase 2b, open‐label study (NCT02776735) consisted of three sequential parts (each with a core‐treatment and extension‐phase). During part 1, three doses were assessed in two weight groups (Group A/B: ≥30–60 kg/≥10–<
Fabrizio De Benedetti, Inmaculada C. Penadés, Irina Nikishina, Ivan Foeldvari, Alberto J. Spindler, Anna Kozlova, Nadina Rubio‐Pérez, Pierre Quartier, Zbigniew Żuber, Raul Barria, Daniel Clemente, Gabriel V. Cornejo, Katherine Marzan, Nancy Liu, Christine Xu, Stephen DiMartino, Angeliki Giannelou, Fei Cao‐Ghoul, Bolanle Akinlade, Lydie Baret‐Cormel   +19 more
wiley   +1 more source

Understanding signaling cascades in melanoma [PDF]

, 2008
Understanding regulatory pathways involved in melanoma development and progression has advanced significantly in recent years. It is now appreciated that melanoma is the result of complex changes in multiple signaling pathways that affect growth control,
Akslen L. A., Berger A. J., Berking C., Bhoumik A., Bhoumik A., Chen X., Claffey K. P., Collisson E. A., Coppock D. L., Dahia P. L. M., Dhawan P., Dorsky R. I., Ehebauer M., Eisenmann K. M., Genersch E., Goding C. R., Goodall J., Gorden A., Guldberg P., Gurzov E. N., Herbst R. A., Hingorani S. R., Hughes M. J., Huguier S., Iozzo R. V., Jonsson M., Jorgensen K., Karin M., Kennedy N. J., Kumar R., Lacal P. M., Li N., Maeno K., Meyskens F. L., Miller J. R., Miyazono K., Niu G., Okuyama R., Omholt K., Park B. K., Piek E., Qin J.-Z., Rangaswami H., Rimm D. L., Rofstad E. K., Satyamoorthy K., Soldatencov V. A., Stewart F. A., Tago K.-i., Thomson J. A., Tokita T., Tsai E. Y., Tsao H., van Elsas A., Wu M., Yang J., Yang J., Yang Y. M., Zhou X. P.   +58 more
core   +1 more source